Home›Stock Screener›Themis Medicare

Themis Medicare Share Price Today | Stock Price & Themis Medicare Share Screener

THEMISMED Pharmaceuticals & Biotechnology
Live Share Price NSE
₹96.98
▲ 0.48 (0.50%)
2026-11-19 00:00:00
Live Share Price BSE
₹97.36
▲ 1.22 (1.27%)
2026-11-19 00:00:00

As of November 19, 2026, the live Themis Medicare share price (NSE: THEMISMED) is ₹96.98 on NSE and ₹97.36 on BSE, up 0.50% from the previous close, with shares trading between ₹96.20 and ₹98.00 in today's trading session, and a 52-week range of ₹66.07–₹133.07. Track Themis Medicare networth to gauge the company's total market size. Use the Themis Medicare stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Themis Medicare opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹87 and net income of ₹9, with EBITDA of ₹14, an operating margin of 5.0% and a profit margin of 10.3%.

Themis Medicare Market Cap ₹905.16 Cr.
THEMISMED P/E Ratio (TTM) 23.40
Themis Medicare P/B Ratio 2.55
EPS (TTM) ₹0.12
Dividend Yield 0.50%
Debt to Equity 0.25
THEMISMED 52 Week High ₹133.07
Themis Medicare 52 Week Low ₹66.07
Operating Margin 5.00%
Profit Margin 10.34%
THEMISMED Revenue (TTM) ₹87.00
EBITDA ₹14.00
Net Income ₹9.00
Total Assets ₹598.00
Total Equity ₹399.00

Themis Medicare Share Price Chart

Track the current stock price of Themis Medicare with an interactive chart. Analyse THEMISMED share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Themis Medicare stock quote in one place.

The quote of ₹96.98 sits between the 52-week low of ₹66.07 and the 52-week high of ₹133.07, and the latest session moved 0.50% from the previous close.

Themis Medicare Company Profile - Fundamental Screener

Screen Themis Medicare company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for THEMISMED shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE083B01024.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE083B01024

Themis Medicare Balance Sheet Screener

Screen THEMISMED balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹598, up from ₹588 in 2025.

Latest statistics put total assets at ₹598 and shareholder funds at ₹399, with a leverage ratio of 0.25.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 598 588 566 514 428 371 350 314 305 289
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 167 172 168 162 144 133 116 123 126 124

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 33 29 34 35 31 24 12 9 12 12
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 399 403 378 339 288 219 183 158 169 152
Share Capital 9 9 9 9 9 9 9 9 9 9
Reserves & Surplus 389 393 369 330 278 209 174 149 160 143

Themis Medicare Income Statement Screener - Profit & Revenue Analysis

Screen Themis Medicare income statement and profit fundamentals. Analyze THEMISMED quarterly results. Themis Medicare reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹87 and net profit was ₹9, equal to earnings per unit of ₹0.96, at an operating margin of 5%.

In that period expenses were ₹73, interest cost ₹3 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹184 and net profit of ₹25.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 87 184 97 73 99 83 97 103 130 123 95 85 103 111 89
Expenses 73 139 84 79 108 81 81 89 94 100 88 70 75 92 74

Operating Costs and Margins

EBITDA 14 44 13 -6 -9 2 16 14 36 23 7 16 28 19 14
Operating Profit % 5.00% -60.00% 6.00% -11.00% -10.00% -4.00% 10.00% 10.00% 24.00% 15.00% 6.00% 13.00% 22.00% 12.00% 10.00%
Depreciation 3 3 3 3 3 3 3 3 2 3 3 3 3 3 3
Interest 3 3 2 3 3 3 3 2 2 2 3 3 3 2 3

Profit and Earnings

Profit Before Tax 9 39 8 -11 -14 -4 10 9 31 18 2 10 23 14 8
Tax 0 14 1 -2 0 0 0 2 7 4 1 2 4 3 1
Net Profit 9 25 7 -10 -14 -4 10 7 25 14 1 8 18 11 7
EPS 0.96 2.67 0.77 -1.05 -1.54 -0.39 1.10 0.72 2.68 1.55 0.06 9.13 19.77 12.30 0.80

Themis Medicare Cash Flow Screener - Liquidity Fundamentals

Screen THEMISMED cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹3, and net cash flow was an outflow of ₹2.

Over the same period, investing activities used ₹3 and financing activities provided ₹4.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities -3 35 22 16 34 57 0 11 8 -2
Investing Activities -3 -12 -16 -24 -16 -16 -6 -4 0 -4

Financing and Net Cash

Financing Activities 4 -26 -9 0 -18 -26 7 -10 -9 5
Net Cash Flow -2 -3 -3 -8 1 16 2 -3 -1 0

Themis Medicare Shareholding Pattern Screener

See Themis Medicare shareholding pattern with promoter, FII, and DII holdings. Check Themis Medicare promoter holding and ownership changes for THEMISMED on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 67.11%, foreign institutions 0.11%, domestic institutions 0.01% and the public 23.73%, spread across 21,818 shareholders.

The shareholder count was 21,818 in 2026-Mar, compared with 21,267 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 67.11% 67.11% 67.11% 67.15% 67.15% 67.15% 67.11% 67.15%

Institutional Investors

FII Holding 0.11% 0.01% 0.01% 0.14% 0.10% 0.06% 0.05% 0.03%
DII Holding 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 23.73% 23.57% 23.26% 23.93% 24.14% 23.97% 24.02% 23.31%
Other Holding 9.05% 9.30% 9.62% 8.77% 8.60% 8.80% 8.81% 9.49%
Shareholder Count 21,818 21,267 20,126 17,889 19,335 22,490 22,576 11,295

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Themis Medicare. Themis Medicare dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.50 per unit for 2026-March, a yield of 0.50%, compared with ₹0.50 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.50, ₹0.50 and ₹0.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.50 0.50%
2025-March ₹0.50 0.76%
2024-March ₹0.50 0.34%
2023-March ₹5.00 2.29%
2022-March ₹5.00 4.24%
2021-March ₹4.30 4.59%
2020-March ₹1.75 6.22%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Themis Medicare Stock Index Membership - Nifty & Sensex

See which indices include Themis Medicare stock. Check THEMISMED index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 2 indices, including BSE INDEX BSE HC.

Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE INDEX BSE HC
BSE INDEX SMLCAP

Themis Medicare Market Events Screener - Corporate Actions

Get Themis Medicare corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Themis Medicare stock events that may affect THEMISMED share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Dividend dated September 23, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-14 2026-11-14 Quarterly Result Announcement NA 10.69%
2026-09-30 2026-09-30 Annual General Meeting NA -9.91%
2026-09-23 2026-09-23 Dividend ₹ 0.50 /share 8.38%
2026-08-13 2026-08-13 Quarterly Result Announcement NA 3.32%
2026-05-28 2026-05-28 Quarterly Result Announcement NA 13.63%
2026-02-13 2026-02-13 Quarterly Result Announcement NA 7.49%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -1.41%
2025-09-12 2025-09-12 Annual General Meeting NA -1.60%
2025-09-04 2025-09-05 Dividend ₹ 0.50 /share -41.32%
2025-08-01 2025-08-01 Quarterly Result Announcement NA -8.21%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 25.64%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -15.07%
2024-10-25 2024-10-25 Quarterly Result Announcement NA 1.15%
2024-07-22 2024-07-22 Annual General Meeting NA 5.80%
2024-07-12 2024-07-15 Dividend ₹ 0.50 /share 9.31%

Themis Medicare Competitors Screener - Peer Stocks Comparison

Screen THEMISMED competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,123 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 298,758 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 179,477 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 125,590 98.10 6,868 22.01% 890 69.60
Zydus Life Science 119,750 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,603 41.70 35,059 3.90% 4,158 70.24
Cipla 112,680 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 109,085 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,719 26.40 34,145 5.56% 3,503 66.06
Lupin 90,877 17.30 29,039 26.75% 5,356 44.92

Themis Medicare Company Announcements - News & Reports Screener

Screen THEMISMED latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 20, 2026 and November 20, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-20 Results: Financial Results For The Quarter And Half Year Ended 30.09.2026 -
2026-11-20 Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.11.2026 -
2026-11-02 Update on board meeting -
2026-10-30 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-28 Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. -
2026-10-28 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-10-27 Board Meeting Intimation for Consideration And Approval Of Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30.09.2026 -
2026-10-24 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-24 Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. -
2026-10-24 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-10-23 Announcement Under Regulation 30 - Updates -
2026-10-23 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-09 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-30 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -
2026-09-30 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹96.98, within a 52-week range of ₹66.07 to ₹133.07. The P/E ratio is 23.40 and the P/B ratio is 2.55, with earnings per unit of ₹0.12. Market capitalisation stands at ₹905.16 Cr and the dividend yield is 0.50%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 21, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.